EcoDrugPlus

Selectin E

Ensembl ID : ENSACIG00000013584
Gene Symbol: SELE
2 Cross references
179 Possible Orthologues:

Selectin P

Ensembl ID : ENSACIG00000013667
Gene Symbol: SELP
1 Cross references
170 Possible Orthologues:

Serpin Peptidase Inhibitor, Clade C (Antithrombin), Member 1

Ensembl ID : ENSACIG00000019810
Gene Symbol: SERPINC1
1 Cross references
202 Possible Orthologues:

Si:dkey-211g8.6

Ensembl ID : ENSACIG00000019287
Gene Symbol: SI:DKEY-211G8.6
1 Cross references
319 Possible Orthologues:

Si:dkey-91m11.5

Ensembl ID : ENSACIG00000010490
Gene Symbol: SI:DKEY-91M11.5
1 Cross references
203 Possible Orthologues:

Smoothened, Frizzled Class Receptor

Ensembl ID : ENSACIG00000019402
Gene Symbol: SMO
1 Cross references
204 Possible Orthologues:

Sodium Channel, Voltage Gated, Type Xii, Alpha A

Ensembl ID : ENSACIG00000010766
Gene Symbol: SCN12AA
1 Cross references
245 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 4

Ensembl ID : ENSACIG00000006500
Gene Symbol: SCN4A
1 Cross references
185 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSACIG00000000902
Gene Symbol: SCN8A
2 Cross references
218 Possible Orthologues:

Solute Carrier Family 10 Member 2

Ensembl ID : ENSACIG00000018698
Gene Symbol: SLC10A2
1 Cross references
211 Possible Orthologues:

Solute Carrier Family 18 Member 2

Ensembl ID : ENSACIG00000024265
Gene Symbol: SLC18A2
1 Cross references
216 Possible Orthologues:

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSACIG00000010094
Gene Symbol: SLC29A1
1 Cross references
207 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).